The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells

Oncology Reports

Volumn 24, Issue 5, 2010, Pages 1395-1399

  Terakawa, Tomoaki ^a   Miyake, Hideaki ^a   Kumano, Masafumi ^a   Sakai, Iori ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Androgen receptor; Antiandrogen withdrawal syndrome; Mitogen activated protein kinase; Prostate cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN RECEPTOR; BICALUTAMIDE; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; TRYPTOPHAN; UO 126;

ARTICLE; CODON; CONTROLLED STUDY; DRUG EFFECT; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; TRANSACTIVATION; WILD TYPE;

ANDROGEN ANTAGONISTS; ANILIDES; CELL LINE, TUMOR; CODON; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NITRILES; POINT MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS;

EID: 78149296654     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000998     Document Type: Article

References (18)

1. Wilson SS and Crawford ED: Controversies of androgen ablation therapy for metastatic prostate cancer. Curr Pharm Des 12: 799-805, 2006.
2. Lukka H, Waldron T, Klotz L, Winquist E and Trachtenberg J: Maximal androgen blockade for the treatment of metastatic prostate cancer - a systematic review. Curr Oncol 13: 81-93, 2006.
3. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T and Miki T: Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180: 921-927, 2008.
4. Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D and Crawford ED: Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 112: 2393-2400, 2008.
5. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO and Mulder E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173: 534-540, 1990.
6. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ and Balk SP: Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 3: 1383-1388, 1997. (Pubitemid 27362400)
7. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM and Feldman D: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6: 703-706, 2000. (Pubitemid 30398797)
8. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M and Miyamoto M: Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63: 149-153, 2003. (Pubitemid 36070433)
9. Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T and Ogawa O: Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 65: 9611-9616, 2005.
10. Miyake H, Nelson C, Rennie PS and Gleave ME: Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141: 2257-2265, 2000. (Pubitemid 32274381)
11. Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H and Fujisawa M: Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 13: 1192-1197, 2007. (Pubitemid 46424060)
12. Kelly WK and Scher HI: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 149: 607-609, 1993.
13. Miyake H, Hara I and Eto H: Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 96: 791-795, 2005. (Pubitemid 41391382)
14. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O and Belldegrun AS: Secondary hormonal therapy for advanced prostate cancer. J Urol 175: 27-34, 2006.
15. Culig Z: Androgen receptor cross-talk with cell signalling pathways. Growth Factors 22: 179-184, 2004.
16. Pitkänen-Arsiola T, Tillman JE, Gu G, Yuan J, Roberts RL, Wantroba M, Coetzee GA, Cookson MS and Kasper S: Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability. Prostate 66: 1177-1193, 2006.
17. Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G and Chang C: Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res 62: 6039-6044, 2002.
18. Bohl CE, Gao W, Miller DD, Bell CE and Dalton JT: Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102: 6201-6206, 2005.